Redeye comments on Annexin’s Q2 report and recent events in the company.
Redeye comments on the takeover offer on Bredband2 from Telia Company.
Q2 outcome Sales was SEK 2,395m (+2% vs. ABG 2,345m, +2% vs.
Redeye provides a short comment on the Q2 2025 report from Sdiptech, which came in below our estimat...
Redeye comments on Truecaller’s Q2 2025 report, which was somewhat softer than expected.
Redeye state Acconeer’s Q2 2025 report fell short of its expectations on both sales and EBITDA.
Redeye retains its positive view of Avensia despite slightly lowering our Base Case and forecasts.
Redeye comments on the negative topline data in the TRIFOUR study and provides a new base case.
Atria's Q2 EBIT of EUR 17.6m came in above LSEG Data & Analytics consensus expectations despite temp...
Redeye notes that Sivers’ Q2 2025 report confirms the company’s solid underlying development, with 4...
Fiskars' Q2 adjusted EBIT fell clearly short of Modular Finance consensus expectations, despite the ...
Redeye retains its positive view of Vertiseit following the Q2 report.
Redeye comments on CombinedX’s Q2 report, showing negative growth and lower margins than expected.
Q2: better momentum for the largest brands In Q1, Boråstapeter returned to organic growth.
Softer across the board The Q2 report was softer than we had expected with regard to all key line it...
Exitmarknaderna har vaknat till liv igen och VEF har använt del av likviden från årets tre exits til...
Atria reported Q2 adjusted EBIT of EUR 17.6m, 7% above LSEG Data & Analytics consensus.
Redeye comments on Avensia’s Q2 report, with sales and EBIT somewhat lower than anticipated.
US decision-making could have been delayed in Q2 During times of global uncertainty, consulting proj...
Redeye comments on OncoZenge’s recent amendment to its licensing agreement with Molteni Farmaceutici...